Japanese Pharmacology & Therapeutics (JPT)
Vol. 49 Suppl. 1 2021
■ The 12th Annual Meeting "Change of Clinical Trials and Research —from First-in-Human to Big Data—"
SYMPOSIUM 1 Flexible Clinical Trial Design Based on Statistical Decision-making
1 Design of Small Clinical Trials
S. Teramukai
Jpn Pharmacol Ther 2021; 49(s1): s9-11.
2 Use of Basket Trial Design in Investigator Initiated Clinical Trials for Molecular-Targeted Agents
I. Yokota, et al
Jpn Pharmacol Ther 2021; 49(s1): s12-15.
SYMPOSIUM 2 Challenge of Digital Trials
1 Efforts of Investigator Initiated Trials for Amyotrophic Lateral Sclerosis (ALS) during the COVID-19 Pandemic
R. Oki, et al
Jpn Pharmacol Ther 2021; 49(s1): s16-18.
2 New Normal of Clinical Trial in Post COVID Era
──Focusing on the Experience of Virtual Clinical Trial, Home-Visiting Clinical Trial, and DCT
H. Nagashima
Jpn Pharmacol Ther 2021; 49(s1): s19-22.
3 Digital Shift of Clinical Trial Operation with Telemedicine and eSource as a New Standard of Post COVID-19
R. Kusama
Jpn Pharmacol Ther 2021; 49(s1): s23-25.
4 Consideration for Introduction and Adoption of Decentralized Clinical Trials in Japan
W. Takasawa
Jpn Pharmacol Ther 2021; 49(s1): s26-28.
■ ORIGINAL ARTICLES
Collaboration between Academia and Private Companies on Implementation of CDISC Standards:
A Survey of Pharmaceutical Companies and Contract Research Organizations（CRO）
T. Yamaguchi, et al
Jpn Pharmacol Ther 2021; 49(s1): s47-56.
Current Status and Promotion of Information Disclosure about Medical Institutions
for Patients Considering Participating in Clinical Trials
M. Yamaguchi, et al
Jpn Pharmacol Ther 2021; 49(s1): s57-62.
■ CASE REPORTS
Web Portal Development to Share Information about CDISC Standards in Academia
M. Yamamoto, et al
Jpn Pharmacol Ther 2021; 49(s1): s63-67.
■ BRIEF REPORTS
Examination of Consultation and Support for Nursing Research throughout
the Year at the Institute for Clinical and Translational Science
M. Uyama, et al
Jpn Pharmacol Ther 2021; 49(s1): s68-71.
■ TECHNOLOGY TRENDS
Bayesian Approaches in Rare Disease Drug Development
A. Hirakawa, et al
Jpn Pharmacol Ther 2021; 49(s1): s72-79.